Noninvasively characterizing the different αvβ3 expression patterns in lung cancers with RGD-USPIO using a clinical 3.0T MR scanner
Tao Jiang1,*, Chunfu Zhang2, Xuan Zheng3,*, Xiongfei Xu4, Xuan Xie2, Hongchao Liu1, Shiyuan Liu1
1Department of Radiology, ChangZheng Hospital Affiliated to Second Military Medical University, 415 Fengyang Road, Shanghai, China; 2Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, China; 3Department of Nutrition, Changhai Hospital Affiliated to Second Military Medical University, Shanghai, China; 4Department of Immunology, Second Military Medical University, Shanghai, China; *These authors contributed equally to this work
Abstract: The adhesion molecule αvβ3 integrin plays an important role in tumor development and metastases. We demonstrated the specificity of the probe to αvβ3 integrin with transmission electron microcopy (TEM) and magnetic resonance imaging (MRI). The in vivo targeting behavior of the probe was examined in 2 tumor models with different αvβ3 expression patterns by a 3.0T MRI scanner. MR imaging showed that R2* pseudo-color pictures of A549 lung cancer tumor was different from that of 3LL lung cancer. For A549 tumor, an homogeneous decrease of signal intensity was observed throughout the tumor, which was more evident in the periphery or central areas. Histological studies revealed that αvβ3 integrin was expressed both on the tumor vessel and tumor cells for A549 tumor. Our findings indicated that it was possible to noninvasively characterize the different αvβ3 expression pattern in lung cancers with arginine-glycine-aspartic acid (RGD) peptide conjugated ultra-small superparamagnetic iron oxide nanoparticles (RGD-USPIO) using a clinical 3.0T MR scanner. Nevertheless, the way of imaging targeting presentation of the probe differed in tumors with different αvβ3 expression patterns.
Keywords: USPIO, RGD peptide, αvβ3 integrin, MR molecular imaging
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]